Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 17;59(4):784.
doi: 10.3390/medicina59040784.

Pan-Cancer Analysis Reveals PPRC1 as a Novel Prognostic Biomarker in Ovarian Cancer and Hepatocellular Carcinoma

Xingqiu Ruan  1   2   3 , Guoliang Cui  1   2 , Changyu Li  4 , Zhiguang Sun  2   5
Affiliations

Pan-Cancer Analysis Reveals PPRC1 as a Novel Prognostic Biomarker in Ovarian Cancer and Hepatocellular Carcinoma

Xingqiu Ruan et al. Medicina (Kaunas). .

Abstract

Background and Objectives: As is well understood, peroxisome proliferator-activated receptor gamma cofactor-related 1 (PPRC1) plays a central role in the transcriptional control of the mitochondrial biogenesis and oxidative phosphorylation (OXPHOS) process, yet its critical role in pan-cancer remains unclear. Materials and Methods: In this paper, the expression levels of PPRC1 in different tumor tissues and corresponding adjacent normal tissues were analyzed based on four databases: The Genotype-Tissue Expression (GTEx), Cancer Cell Line Encyclopedia (CCLE), The Cancer Genome Atlas (TCGA), and Tumor Immune Estimation Resource (TIMER). Meanwhile, the prognostic value of PPRC1 was inferred using Kaplan-Meier plotter and forest-plot studies. In addition, the correlation between PPRC1 expression and tumor immune cell infiltration, immune checkpoints, and the tumor-stemness index was analyzed using TCGA and TIMER databases. Results: According to our findings, the expression level of PPRC1 was found to be different in different cancer types and there was a positive correlation between PPRC1 expression and prognosis in several tumor types. In addition, PPRC1 expression was found to be significantly correlated with immune cell infiltration, immune checkpoints, and the tumor-stemness index in both ovarian and hepatocellular carcinoma. Conclusions: PPRC1 demonstrated promising potential as a novel biomarker in pan-cancer due to its potential association with immune cell infiltration, expression of immune checkpoints, and the tumor-stemness index.

Keywords: PPRC1; expression; immune checkpoint; pan-cancer; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Pan-cancer expression of PPRC1. The expression level of PPRC1 in normal tissues from the GTEx database (A) and different tumor cell lines in the CCLE database. The expression of PPRC1 in normal and tumor tissues was explored in integrated datasets containing TCGA (B) and GTEx datasets (C), and in the TIMER database (D). * p < 0.05; ** p < 0.01; *** p < 0.001, **** p < 0.0001.
Figure 2
Figure 2
The association of PPRC1 with OS. Kaplan–Meier-plotted survival analysis of different expression levels of PPRC1 from the TCGA database. The OS of ACC (A), BLCA (B), KIRP (C), LIHC (D), OV (E), and SKCM (F) in patients with higher or lower PPRC1 expression. The forest plot shows the hazard ratios of PPRC1 in pan-cancer (G).
Figure 3
Figure 3
The association of PPRC1 with DSS. Kaplan–Meier-plotted survival analysis revealed the DSS of ACC (A), ESCA (B), KIRP (C), and LIHC (D) in patients with different expression levels of PPRC1. The forest plot showed the hazard ratios of PPRC1 in pan-cancer (E).
Figure 4
Figure 4
The association of PPRC1 with PFI. Kaplan–Meier-plotted survival analysis revealed the PFI of ACC (A), BLCA (B), GBM (C), KIRP (D), LIHC (E), and UVM (F). The forest plot shows the hazard ratios of PPRC1 in pan-cancer (G).
Figure 5
Figure 5
The correlation of PPRC1 expression and immune cell infiltration. * p < 0.05; ** p < 0.01; *** p < 0.001, **** p < 0.0001.
Figure 6
Figure 6
The correlation of PPRC1 expression and tumor immune checkpoints. * p < 0.05; ** p < 0.01; *** p < 0.001.
Figure 7
Figure 7
The correlation of PPRC1 expression and tumor-stemness index.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Miller K.D., Ortiz A.P., Pinheiro P.S., Bandi P., Minihan A., Fuchs H.E., Martinez Tyson D., Tortolero-Luna G., Fedewa S.A., Jemal A.M., et al. Cancer statistics for the US Hispanic/Latino population, 2021. CA Cancer J. Clin. 2021;71:466–487. doi: 10.3322/caac.21695. - DOI - PubMed
    1. Byrd D.R., Brierley J.D., Baker T.P., Sullivan D.C., Gress D.M. Current and future cancer staging after neoadjuvant treatment for solid tumors. CA Cancer J. Clin. 2021;71:140–148. doi: 10.3322/caac.21640. - DOI - PubMed
    1. Liu X., Yu S., Feng C., Mao D., Li J., Zhu X. In Situ Analysis of Cancer Cells Based on DNA Signal Amplification and DNA Nanodevices. Crit. Rev. Anal. Chem. 2021;51:8–19. doi: 10.1080/10408347.2019.1674631. - DOI - PubMed
    1. Urbanek-Trzeciak M.O., Galka-Marciniak P., Nawrocka P.M., Kowal E., Szwec S., Giefing M., Kozlowski P. Pan-cancer analysis of somatic mutations in miRNA genes. EBioMedicine. 2020;61:103051. doi: 10.1016/j.ebiom.2020.103051. - DOI - PMC - PubMed
    1. Liu J., Wang Y., Yin J., Yang Y., Geng R., Zhong Z., Ni S., Liu W., Du M., Yu H., et al. Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy. J. Oncol. 2022;2022:3477148. doi: 10.1155/2022/3477148. - DOI - PMC - PubMed

Substances